Equities Analysts Issue Forecasts for Agenus Q1 Earnings

Agenus Inc. (NASDAQ:AGEN) – Research analysts at HC Wainwright lowered their Q1 2026 EPS estimates for Agenus in a report released on Monday, March 16th. HC Wainwright analyst E. Bodnar now expects that the biotechnology company will post earnings per share of $1.45 for the quarter, down from their previous forecast of $1.49. The consensus estimate for Agenus’ current full-year earnings is ($12.55) per share. HC Wainwright also issued estimates for Agenus’ Q2 2026 earnings at ($0.56) EPS, Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.21) EPS and FY2026 earnings at $0.41 EPS.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Agenus in a research note on Monday, December 29th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Agenus has an average rating of “Hold” and a consensus price target of $14.50.

Agenus Trading Down 5.8%

Shares of AGEN opened at $3.76 on Wednesday. The firm has a market capitalization of $144.38 million, a price-to-earnings ratio of -8.17 and a beta of 1.57. The firm’s fifty day simple moving average is $3.27 and its 200-day simple moving average is $3.77. Agenus has a twelve month low of $1.38 and a twelve month high of $7.34.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Monday, March 16th. The biotechnology company reported $0.56 EPS for the quarter, topping the consensus estimate of ($1.27) by $1.83. Agenus had a negative net margin of 2.67% and a negative return on equity of 7.65%. The company had revenue of $34.20 million during the quarter, compared to analysts’ expectations of $28.10 million.

Institutional Trading of Agenus

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AGEN. Renaissance Technologies LLC lifted its position in shares of Agenus by 721.1% during the 4th quarter. Renaissance Technologies LLC now owns 543,546 shares of the biotechnology company’s stock worth $1,707,000 after buying an additional 477,346 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Agenus in the 2nd quarter valued at $1,976,000. AQR Capital Management LLC raised its stake in Agenus by 3,080.3% during the 1st quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock worth $664,000 after acquiring an additional 427,604 shares in the last quarter. Bank of America Corp DE raised its stake in Agenus by 110.0% during the 2nd quarter. Bank of America Corp DE now owns 420,678 shares of the biotechnology company’s stock worth $1,922,000 after acquiring an additional 220,327 shares in the last quarter. Finally, Walleye Capital LLC purchased a new stake in Agenus in the second quarter valued at $906,000. Institutional investors and hedge funds own 61.46% of the company’s stock.

Agenus News Roundup

Here are the key news stories impacting Agenus this week:

• Positive Sentiment: Q4 results materially beat expectations — Agenus reported $0.56 EPS and $34.2M revenue for Q4, outperforming consensus and showing revenue strength versus estimates; this beat supports upside to sentiment and validates recent clinical/commercial execution. View Press Release
• Positive Sentiment: Agenus will present preliminary investigator‑sponsored data for botensilimab + balstilimab in first‑line MSS metastatic colorectal cancer at AACR 2026 — a high‑visibility scientific forum that could generate clinical interest, potential partnering or investor re‑rating if results look promising. Agenus Announces Upcoming AACR 2026 Presentation
• Neutral Sentiment: Short‑interest reports show a stated “large increase” but the published figures are inconsistent/zero (days‑to‑cover reported as 0.0), indicating a likely reporting/data glitch rather than clear bearish positioning; monitor subsequent filings for clarity. (No external article link was provided for the raw short‑interest entries.)
• Negative Sentiment: HC Wainwright trimmed EPS estimates across multiple 2026 quarters and lowered FY2026 from $0.58 to $0.41 — the analyst cuts reduce near‑term earnings visibility and may weigh on sentiment, especially after the post‑earnings re‑rating. HC Wainwright Estimate Cuts (MarketBeat)

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.